News & Views

Cancer health disparities

LGBTQ Patients With Cancer

Recognized by the National Academies of Medicine as a population vulnerable to health disparities, people who identify as lesbian, gay, bisexual, transgender, or queer (LGBTQ) experience specific health disparities, including limited access to health care, increased risk for certain disease types, and an inherent bias in the health system.

Trending Topics

View All Topics

FDA Approves Ramucirumab Plus Erlotinib for First-Line Treatment of Metastatic NSCLC

Oncology drug research

FDA Approves Ramucirumab Plus Erlotinib for First-Line Treatment of Metastatic NSCLC

COVID-19 Challenges Showcase Stories of Nurses’ Strength

COVID-19 Challenges Showcase Stories of Nurses’ Strength

Be Honest: Are You Getting Enough Sleep?

Nurse well-being

Be Honest: Are You Getting Enough Sleep?

FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC

Oncology drug research

FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC

Proton Therapy May Reduce Radiation’s Severe Side Effects

Radiation therapy

Proton Therapy May Reduce Radiation’s Severe Side Effects

FDA Approves Brigatinib for ALK-Positive, Metastatic NSCLC

U.S. Food and Drug Administration (FDA)

FDA Approves Brigatinib for ALK-Positive, Metastatic NSCLC

Oncology Drug Reference Sheet: Capecitabine

Prescription medication

Oncology Drug Reference Sheet: Capecitabine

FDA Approves Olaparib for HRR Gene-Mutated, Metastatic, Castration-Resistant Prostate Cancer

Oncology drug research

FDA Approves Olaparib for HRR Gene-Mutated, Metastatic, Castration-Resistant Prostate Cancer

Innovative Clinics Help Patients Safely Access Cancer Care During COVID-19

Innovative Clinics Help Patients Safely Access Cancer Care During COVID-19

Investigational Maintenance Therapy Extends Survival in AML

Cancer treatments

Investigational Maintenance Therapy Extends Survival in AML

FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression

U.S. Food and Drug Administration (FDA)

FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression

The Case of the Medication Modification

Treatment side effects

The Case of the Medication Modification

FDA Approves Ripretinib for Advanced Gastrointestinal Stromal Tumor

U.S. Food and Drug Administration (FDA)

FDA Approves Ripretinib for Advanced Gastrointestinal Stromal Tumor

FDA Grants Accelerated Approval to Rucaparib for BRCA-Mutated, Metastatic, Castration-Resistant Prostate Cancer

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Rucaparib for BRCA-Mutated, Metastatic, Castration-Resistant Prostate Cancer

FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic Non-Small Cell Lung Cancer

U.S. Food and Drug Administration (FDA)

FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic Non-Small Cell Lung Cancer

Spotlight on Melanoma

Melanoma Prevention, Screening, Treatment, and Survivorship Recommendations

FDA Grants Accelerated Approval to Pomalidomide for Kaposi Sarcoma

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Pomalidomide for Kaposi Sarcoma

Family Risk Factors May Indicate Need for Genetics Counseling Referrals

Genetics & genomics

Family Risk Factors May Indicate Need for Genetics Counseling Referrals

Dietary Supplements May Affect Breast Cancer Chemo Outcomes

Dietary Supplements May Affect Breast Cancer Chemo Outcomes

Share Your Comments About Hazardous Drugs With NIOSH

Oncology drug research

Share Your Comments About Hazardous Drugs With NIOSH

COVID-19 patient education

Clinical practice

COVID-19 Talking Points for Patients With Cancer, Caregivers, and Family Members

Research Is Needed to Better Understand Combination Immunotherapy Side Effects

Research Is Needed to Better Understand Combination Immunotherapy Side Effects

FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

U.S. Food and Drug Administration (FDA)

FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions

U.S. Food and Drug Administration (FDA)

FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions

How to Prevent Opioid Misuse While Effectively Managing Cancer Pain

Pain management

How to Prevent Opioid Misuse While Effectively Managing Cancer Pain

ONS Congress, Chapter Leadership, and Business Meetings Go Virtual

ONS Congress, Chapter Leadership, and Business Meetings Go Virtual

ONS Member Receives ASCO Award for Transforming Cancer Palliative Care

ONS Member Receives ASCO Award for Transforming Cancer Palliative Care

FDA Grants Accelerated Approval to Capmatinib for Metastatic Non-Small Cell Lung Cancer

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Capmatinib for Metastatic Non-Small Cell Lung Cancer

Nurses Address Barriers to Care Through CoC’s Revised Standards

Cancer health disparities

Nurses Address Barriers to Care Through CoC’s Revised Standards

Meet Your ONS Leader: Marty Polovich, PhD, RN

Meet Your ONS Leader: Marty Polovich, PhD, RN

Remodeled CAR T-Cell Therapy May Reduce Side Effects

Cancer treatments

Remodeled CAR T-Cell Therapy May Reduce Side Effects

Harnessing the Abscopal Effect May Change Cancer Care

Radiation therapy

Harnessing the Abscopal Effect May Change Cancer Care

The Next Frontier for Oncology Nursing Care

Combination Immunotherapy

FDA Approves Daratumumab and Hyaluronidase-Fihj for Multiple Myeloma

U.S. Food and Drug Administration (FDA)

FDA Approves Daratumumab and Hyaluronidase-Fihj for Multiple Myeloma

Nursing Innovation, Leadership, and Dedication Shine During Pandemic

Nursing Innovation, Leadership, and Dedication Shine During Pandemic

Unique Roles in Oncology Nursing: Oncology Nurse Navigation

Nurse navigator

Unique Roles in Oncology Nursing: Oncology Nurse Navigation

FDA Approves New Dosing Regimen for Pembrolizumab

U.S. Food and Drug Administration (FDA)

FDA Approves New Dosing Regimen for Pembrolizumab

FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer

U.S. Food and Drug Administration (FDA)

FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer

The Evidence for Herbal Supplements for Immunity and Stress During COVID-19

The Evidence for Herbal Supplements for Immunity and Stress During COVID-19

Oncology Drug Reference Sheet: Daratumumab

Oncology drug research

Oncology Drug Reference Sheet: Daratumumab

Meet Your ONS Leader: Heather Thompson Mackey, MSN, ANP-BC, AOCN®

Meet Your ONS Leader: Heather Thompson Mackey, MSN, ANP-BC, AOCN®

FDA Grants Accelerated Approval to Sacituzumab Govitecan-Hziy for Metastatic Triple-Negative Breast Cancer

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Sacituzumab Govitecan-Hziy for Metastatic Triple-Negative Breast Cancer

FDA Announces Leucovorin Drug Shortage

U.S. Food and Drug Administration (FDA)

FDA Announces Leucovorin Drug Shortage

FDA Approves Ibrutinib Plus Rituximab for Chronic Lymphocytic Leukemia

U.S. Food and Drug Administration (FDA)

FDA Approves Ibrutinib Plus Rituximab for Chronic Lymphocytic Leukemia

Drug Combo May Be Effective for BRCA-Mutated Pancreatic Cancer

Pancreatic cancer

Drug Combo May Be Effective for BRCA-Mutated Pancreatic Cancer

Oral and Oropharyngeal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations

Cancer screening

Oral and Oropharyngeal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations

FDA Approves First Targeted Treatment for Patients With Cancer of Bile Ducts

U.S. Food and Drug Administration (FDA)

FDA Approves First Targeted Treatment for Patients With Cancer of Bile Ducts

FDA Approves First New Drug Under International Collaboration, a Treatment Option for Patients With HER2-Positive Metastatic Breast Cancer

U.S. Food and Drug Administration (FDA)

FDA Approves First New Drug Under International Collaboration, a Treatment Option for Patients With HER2-Positive Metastatic Breast Cancer 

International Position Statement Calls for Advocacy for COVID-19 in Oncology Nurses and Patients With Cancer

Cancer healthcare advocacy

International Position Statement Calls for Advocacy for COVID-19 in Oncology Nurses and Patients With Cancer

Back to Top ▲